Antisense Therapeutics
Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company developing RNA-based antisense oligonucleotide therapies targeting genetically determined conditions including elevated Lipoprotein(a) and Duchenne Muscular Dystrophy. It serves patients with high unmet medical need and is publicly listed on the ASX.
- Company typePrivate
- Founded2000
- HeadquartersMelbourne, Australia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Antisense Therapeutics does
Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company founded in 2000 and headquartered in Melbourne, listed on the Australian Securities Exchange (ASX: ANP). The company specializes in the discovery and development of RNA-based antisense oligonucleotide therapies and siRNA technologies for targeted genetic intervention in diseases with high unmet medical need.
The company's lead therapeutic program targets elevated Lipoprotein(a) — a genetically determined cardiovascular risk factor affecting approximately 20% of the global population that is largely unresponsive to lifestyle modifications or conventional therapies. In early-phase clinical trials, the company's antisense oligonucleotide therapy has demonstrated up to 98% reduction in Lp(a) levels, representing a potentially significant therapeutic advance for atherosclerotic cardiovascular disease prevention. The company also has positioning within the Duchenne Muscular Dystrophy therapeutic market, forecast to reach $6.01 billion by 2030.
The business operates with a lean team of 1-10 employees, led by CEO and Managing Director Mark Diamond, with Phillip Hains serving as CFO and Company Secretary. Revenue generation has not yet commenced as the company remains in clinical development, with operations funded through equity capital raises — including a $5.5 million raise in January 2020 and an earlier $2.1 million round in 2008. The go-to-market model is anticipated to follow traditional pharmaceutical prescription-based distribution channels once products receive regulatory approval, though specific pricing and channel strategies are not publicly disclosed.
Antisense Therapeutics firmographics
Firmographics- Name
- Antisense Therapeutics
- Legal name
- Antisense Therapeutics
- Website
- https://antisense.com.au
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Antisense Therapeutics is an Australian clinical-stage biopharmaceutical company developing RNA-based antisense oligonucleotide therapies targeting genetically determined conditions including elevated Lipoprotein(a) and Duchenne Muscular Dystrophy. It serves patients with high unmet medical need and is publicly listed on the ASX.
- Ownership category
- akta.pro rank
Antisense Therapeutics industry classification
Industry- Product category
- Biopharmaceutical antisense oligonucleotide therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
Keywords
Where Antisense Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Melbourne
- HQ country
- Australia
- HQ region
- Oceania
Markets served
Antisense Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Antisense Therapeutics product offering
Product offeringCore offering
Antisense Therapeutics is a biopharmaceutical drug discovery and development company developing RNA-based antisense oligonucleotide therapies. Its lead programs target genetically determined elevated Lipoprotein(a), a causal risk factor for atherosclerotic cardiovascular disease affecting approximately 20% of the global population, with early-phase trials demonstrating up to 98% reduction in Lp(a) levels. The company is also pursuing therapies for Duchenne Muscular Dystrophy.
Differentiator
Problem solved
Functional benefit
Products and services
- RNA-based Antisense Oligonucleotide Therapies
Quantifiable outcome
- Up to 98% reduction in Lipoprotein(a) in early-phase clinical trials
Companies that use Antisense Therapeutics
Customer profileSegments1 record
Ideal customer profiles3 records
Antisense Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Antisense Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Antisense Therapeutics competitors and assessment
Company assessmentBroad incumbents
- Amgen: Advancing olpasiran, an siRNA therapy for Lp(a) reduction, in late-stage trials. Comparable as a large-cap entrant into the same Lp(a) therapeutic space with RNA-based modality.
- Novartis: Developing pelacarsen, a leading Lp(a)-lowering antisense oligonucleotide in Phase 3 trials. A broad incumbent whose cardiovascular franchise overlaps directly with Antisense Therapeutics' lead indication.
- Alnylam Pharmaceuticals: Leader in RNAi therapeutics with approved products and cardiovascular pipeline. Comparable in RNA-based therapeutic platform and cardiometabolic disease focus.
- Regeneron Pharmaceuticals: Has an active Lp(a) program using siRNA technology. A large-cap incumbent whose cardiovascular pipeline overlaps with the same genetic risk factor Antisense Therapeutics targets.
Emerging players
- Sarepta Therapeutics: Specializes in RNA-targeted therapeutics, notably for Duchenne Muscular Dystrophy, an indication overlapping with Antisense Therapeutics' pipeline. Comparable in oligonucleotide modality and rare disease focus.
- ProQR Therapeutics: Clinical-stage RNA therapy company developing oligonucleotide-based treatments for rare diseases. Comparable as a small-cap RNA therapeutics peer with similar platform approach.
- Wave Life Sciences: Clinical-stage oligonucleotide therapeutics company with programs in cardiovascular and rare diseases. Comparable as an emerging player in the same antisense/oligonucleotide modality space.
Direct peers
- Silence Therapeutics: Clinical-stage company developing siRNA therapies for cardiovascular indications including SLN360 for elevated Lp(a). Closely comparable in modality, target indication, and development stage.
- Ionis Pharmaceuticals: Pioneer of antisense oligonucleotide technology with multiple approved and clinical-stage assets targeting cardiovascular and rare diseases. Directly comparable in platform technology and cardiometabolic focus.
- Arrowhead Pharmaceuticals: Develops RNAi-based therapies for cardiovascular and metabolic diseases, with multiple clinical-stage programs. Directly comparable in RNA-based modality and cardiovascular target overlap.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Antisense Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Antisense Therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
Antisense Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Antisense Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Antisense Therapeutics
What does Antisense Therapeutics do?
Antisense Therapeutics is a biopharmaceutical drug discovery and development company developing RNA-based antisense oligonucleotide therapies. Its lead programs target genetically determined elevated Lipoprotein(a), a causal risk factor for atherosclerotic cardiovascular disease affecting approximately 20% of the global population, with early-phase trials demonstrating up to 98% reduction in Lp(a) levels. The company is also pursuing therapies for Duchenne Muscular Dystrophy.
Is Antisense Therapeutics a public or private company?
Antisense Therapeutics is a private company. It is classified as public and is currently operating.
When was Antisense Therapeutics founded?
Antisense Therapeutics was founded in 2000. It employs 1 to 10 people.
Where is Antisense Therapeutics based?
Antisense Therapeutics is headquartered in Melbourne, Australia, in the Oceania region.
Who are Antisense Therapeutics's main competitors?
Broad incumbents on record are Amgen, Novartis, Alnylam Pharmaceuticals and Regeneron Pharmaceuticals. Emerging players are Sarepta Therapeutics, ProQR Therapeutics and Wave Life Sciences. Direct peers are Silence Therapeutics, Ionis Pharmaceuticals and Arrowhead Pharmaceuticals.
Does Antisense Therapeutics have an API?
No public API is recorded for Antisense Therapeutics.
What industry is Antisense Therapeutics in?
Antisense Therapeutics's product category is Biopharmaceutical antisense oligonucleotide therapeutics. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2836.